Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07778316 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

Name: Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) — clinical trial record (NCT07778316)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DeLLphi-315

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2026-08-31

View on ClinicalTrials.gov ↗

The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.

Trial Details

NCT Number	NCT07778316
Lead Sponsor	Amgen
Conditions	Small Cell Lung Cancer
Enrollment	400 participants
Start Date	2026-08-31
Primary Completion	2027-09-24 (estimated)
Study Completion	2030-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-21